Is Deflazacort currently on the market?

The original drug of Deflazacort () is relatively limited in the global market, but its clinical value has been widely recognized. The United States approved the marketing of deflazacort in 2017 under the trade name Emflaza, which is mainly used to treat patients with Duchenne muscular dystrophy aged 2 years and above. The drug's approval is based on long-term clinical study results, which show that it has significant efficacy in delaying the decline of muscle function and improving the ability to perform daily activities, while having fewer side effects on bone density and weight gain than traditional steroids.

In other countries and regions, deflazacort has not yet been fully marketed, and its clinical use is mainly obtained through clinical trials, imported drugs or generic drugs. In overseas markets, the European version of the original drug is usually 6mg*100 tablets. At the same time, India and other countries have also produced generic drugs with the same ingredients as the original drug and can be used as an alternative. This drug has rich experience in international application, especially in the treatment of DMD. Its long-term efficacy and relatively mild side effects make it one of the standard treatment drugs recommended by multinational guidelines.

Although deflazacort has not yet been launched in China, with the popularity of international guidelines and the increase in clinical demand, domestic doctors and patients have continued to pay more attention to it. When treatingDMD or other indications, medical institutions usually combine international experience to provide individualized medication plans, including dosage, treatment courses and follow-up plans, to ensure that patients get the best treatment results. At the same time, patients need to regularly monitor blood sugar, blood pressure, bone density and growth indicators while using deflazacort, and adjust the dosage and course of treatment in a timely manner to ensure a balance between safety and efficacy.

Overall, deflazacort, as a glucocorticoid with clear indications and unique pharmacological advantages, has played an important role in the globalDMD treatment. Although it has not yet been launched in some countries, its overseas application experience and clinical research results provide patients with a scientific and safe treatment reference, and also lay the foundation for future domestic launch and clinical promotion.

Reference: https://www.drugs.com/mtm/deflazacort.html